Human papillomavirus (HPV) is the most common sexually transmitted infection, and it is estimated that 85% of all women will be infected during their lifetime, often without experiencing symptoms.

Some types of HPV are called high risk HPV as they are associated with an increased risk of cervical cancer which is the fourth most common cancer in women.

Currently, there are no approved therapeutic treatments for high-risk HPV infections.

We are conducting a study looking at a new investigational treatment for HPV that aims to eliminate HPV infection in affected cells.

You may be eligible to take part in this study if you meet the following criteria:

• People with a cervix aged 25 to 55.
• Must have at least one test showing a positive high-risk HPV result (such as HPV 16+, HPV 18+ or HPV 12 Other +) at least 12 months before screening.
• Be in generally good health.

Other inclusion and exclusion criteria apply.

Study treatment is provided free of charge and eligible participants will be reimbursed for study visits and reasonable study-related travel expenses.

Study duration:

The study will have a duration of approximately 30 weeks and there will be 10 in-person clinic visits.

This study is being run at the following clinics and Approved by Central Adelaide Local Health Network Human Research Ethics Committee (CALHN HREC)

• Momentum (AusTrials) Wellers Hill – Brisbane, QLD
• Momentum (AusTrials) Taringa – Brisbane, QLD